Management, Corporate Officers and Directors
The North Cell management team includes individuals with backgrounds in science, research and development of pharmaceutical products, and who also have marketing, management and legal skills and experience. North Cell’s management team is dedicated to developing, protecting and exploiting the licensed proprietary technology to the greatest extent possible. The inventor, Dr. Alain Martin, is the Chief Executive Officer (CEO) and Chief Technical Officer (CTO) of the corporation.
top

Alain Martin, Ph.D. CEO, CTO and Founder
Dr. Martin , who is currently President of Cellular Sciences, Inc., will coordinate all corporate business functions. Cellular Sciences, Inc. (CSI), is a closely held corporation of which he is the principle shareholder and a director. CSI is engaged in the development of proprietary technology for the treatment of lung diseases. Dr. Martin has 30 years of experience in the biotechnology industry. Previously, Dr. Martin was Senior Manager of Business development for the Consumer Products Division, Warner-Lambert Company, a two billion dollar operation. He was responsible for the creation, development, and licensing of technologies that would meet the business needs of Warner-Lambert. He worked on projects that required managing FDA submissions, clinical and research programs. Dr. Martin created technologies that enhanced the penetration of drugs and enhanced the healing of damaged tissues and organs. His ability to commercialize technologies resulted in 24 granted patents. Dr. Martin’s patented technologies are currently being used in six Warner-Lambert products generating $718M in annual sales. They include : Neosporin $460M, Lubriderm $89M, Cool Mint Listerine $121M, and three Schick products $48M. While at Warner-Lambert, Dr. Martin was the recipient of the President’s Award for the creation of innovative new technologies. Dr. Martin’s work was also the recipient of the American Surgeon Gold Medal Award for the creation of new wound healing technologies. Dr. Martin was a member of the Board of Directors of DIAD (Drug Innovation and Design) a development drug company in Boston. He helped establish the overall business development strategy to commercialize DIAD’s antiviral and cancer drugs. Dr. Martin was also a member of MIT (Massachusetts Institute of Technology) Board of Directors of the Industrial Consortium. The Consortium provides business expertise to commercialize MIT intellectual property.
top

R. Dale Winget, Esq.
Mr. Winget is General Counsel to North Cell and was admitted to the bar in New Jersey and Texas and admitted to the United States District Courts for the District of New Jersey and the Northern District of Texas. He is a member of both State and County Bar Associations and has practiced law since 1960.
top

Albert R. Murray Jr., Esquire
Mr. Murray specializes in legal and business management, complex litigation, and international business law. In practice since 1974, he is versed in all aspects of Federal criminal and civil litigation in all jurisdictions of the United States. Mr. Murray has conducted Special Investigations for Government, Institutional, and Corporate clients. He is a former United States Department of Justice Senior Litigation Counsel and Assistant United States Attorney for the Middle District of Pennsylvania. Mr. Murray is a Member of the Bar of the States of Pennsylvania and New York, and admitted to the Supreme Court of the United States; Appellate Division of the Supreme Court of the State of New York; United States Court of Appeals for the Third Circuit; United States District Court for the Middle District of Pennsylvania; and Supreme Court of Pennsylvania.
top

Ronald J. Amen Ph.D.,
Dr. Amen is responsible for regulatory affairs and assisting with drug development. Dr. Amen has over twenty-five years of management and consulting experience in the food, nutrition and pharmaceutical industries. His management positions within the pharmaceutical industry include new drug and nutritional research, product development, and international licensing and acquisitions. Dr. Amen’s has also provided consulting services to the pharmaceutical, nutritional, and medical device industries by contributing business development, marketing strategy, licensing and acquisition support, new product development and clinical and regulatory services. He is a founder of three pharmaceutical companies, and a machine vision system company, and is presently on the Board of Directors of five start-up technology-based companies.
top